Table 1.
Patient and Tumor Characteristics, and Risk of Death from Breast Cancer According to NPNT Positive Staining Pattern
| Patient and Tumor Characteristics | NPNT Phenotype Positive Cases |
All Casesd | |||||
|---|---|---|---|---|---|---|---|
| Nuclear Staininga | Diffuse Cytoplasmic Stainingb | Single Cells Positive | Granular Cytoplasmic Stainingc | Granular Cytoplasmic Staining <10% | Granular Cytoplasmic Staining ≥10% | ||
| Number of cases (%) | 385 (45.7) | 424 (50.4) | 129 (15.3) | 116 (13.8) | 60 (7.1) | 56 (6.7) | 842 |
| Mean age at diagnosis (SD) | 73.0 (9.7) | 72.6 (9.8) | 71.3 (10.4) | 72.8 (9.3) | 72.3 (9.2) | 73.3 (9.4) | 72.0 (10.4) |
| Stage at diagnosis (%, 95% CI) | |||||||
| I | 180 (44, 39-49) | 200 (49, 44-54) | 74 (18, 14-22) | 62 (15, 12-19) | 29 (7, 5-10) | 33 (8, 5-11) | 411 (49) |
| II | 158 (47,42-53) | 178 (53, 48-59) | 42 (13, 9-16) | 41 (12, 9-16) | 23 (7, 4-10) | 18 (5, 3-8) | 333 (40) |
| III | 26 (51, 37-65) | 21 (41, 28-55) | 6 (12, 3-21) | 7 (14, 4-23) | 5 (10, 2-18) | 2 (4, 0-9) | 51 (6) |
| IV | 20 (49, 33-64) | 24 (59, 43-74) | 7 (17, 5-29) | 6 (15, 4-26) | 3 (7, 0-15) | 3 (7, 0-15) | 41 (5) |
| Lymph node status at diagnosis (%, 95% CI) | |||||||
| Positive | 141 (47, 42-53) | 152 (51, 45-57) | 39 (13, 9-17) | 35 (12, 8-15) | 22 (7, 4-10) | 13 (4, 2-7) | 297 (35) |
| Negative | 129 (49, 43-55) | 139 (53, 47-59) | 48 (18, 14-23) | 37 (14, 10-18) | 13 (5, 2-8) | 24 (9, 6-13) | 264 (31) |
| Negative, <5 nodese | 30 (45, 33-58) | 31 (47, 35-59) | 13 (20, 10-29) | 11 (17, 8-26) | 7 (11, 3-18) | 4 (6, 0-12) | 66 (8) |
| Unknown | 85 (40, 33-46) | 102 (47, 41-54) | 29 (13, 9-18) | 33 (15, 11-20) | 18 (8, 5-12) | 15 (7, 4-10) | 215 (26) |
| Molecular subtype (%, 95% CI) | |||||||
| Luminal A | 202 (50, 45-55) | 191 (47, 42-52) | 43 (11, 8-14) | 45 (11, 8-14) | 22 (5, 3-8) | 23 (6, 3-8) | 404 (48) |
| Luminal B HER2- | 93 (41, 35-47) | 127 (56, 49-62) | 61 (27, 21-33) | 36 (16, 11-21) | 22 (10, 6-14) | 14 (6, 3-9) | 227 (27) |
| Luminal B HER2+ | 24 (38, 26-49) | 44 (69, 57-80) | 13 (20, 10-30) | 10 (16, 7-25) | 4 (6, 3-12) | 6 (9, 2-17) | 64 (8) |
| HER2 type | 28 (49, 36-62) | 29 (51, 38-64) | 4 (7, 0-14) | 11 (19, 9-30) | 6 (11, 2-19) | 5 (9, 1-16) | 57 (7) |
| Five negative | 12 (40, 22-58) | 14 (47, 28-65) | 2 (7, 0-16) | 3 (10, 0-21) | 2 (7, 0-16) | 1 (3, 0-10) | 30 (4) |
| Basal | 26 (43, 31-56) | 19 (32, 20-44) | 6 (10, 2-18) | 11 (18, 8-28) | 4 (7, 0-13) | 7 (12, 3-20) | 60 (7) |
| Number of breast cancer deaths | 154 | 164 | 50 | 48 | 29 | 19 | 331 |
| Age-adjusted HR (95% CI)f | 1.12 (0.90-1.39) | 1.04 (0.84-1.30) | 0.98 (0.72-1.32) | 1.24 (0.91-1.70) | 1.61 (1.10-2.37) | 0.92 (0.57-1.47) | - |
Abbreviations: SD: standard deviation, CI: confidence interval, HR: hazard ratio.
a
Negative: <1% positive tumor cells, positive: ≥1% positive tumor cells.
b
Negative: staining index 0-2, positive: staining index ≥3.
c
<10% and ≥10% granular cytoplasmic staining combined.
d
Regardless of NPNT expression.
e
Negative, but less than 5 nodes examined.
f
Adjusted for age at diagnosis in 5-year categories; reference group is patients with negative staining pattern for the respective phenotype.